Skip to main content
Signal8
Launch Terminal

XBiotech Inc. (XBIT)

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

XBiotech Inc. logo

XBiotech Inc.

NASDAQ:XBITHealthcare
-3.09%$1.88
AH$1.88+0.00%vs close
Mkt Cap$57.32M
Float22.25M
O/S30.49M
Vol
$ Vol
RVOL
Inst Own6.5%
SI1.4%
Earnings
Dilution
XBiotech Inc. logoNASDAQ:XBIT$1.88-3.09%
Phase Distribution
8 lead-sponsored trials·0 active·5 completed
Phase 12
Phase 1/22
Phase 24
Status Overview
Not yet recruiting2
Completed5
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Completed

    Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

    Natrunix, Placebo

    Rheumatoid Arthritis

    Enrollment
    243
    Start
    Aug 2023
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT05363891
  • Phase 2
    Unknown status

    Natrunix Versus Methotrexate in Rheumatoid Arthritis

    Natrunix with MTX placebo (+folate), Natrunix placebo with MTX (+folate)

    Rheumatoid Arthritis

    Enrollment
    150
    Start
    Jun 2022est.
    Primary Completion
    Dec 2022est.
    Completion
    Feb 2023est.
    NCT05363917
  • Phase 2
    Not yet recruiting

    Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy

    vilamakitug, placebo

    Axial Spondyloarthritis, Ankylosing Spondylitis +2

    Enrollment
    150
    Start
    Sep 2026est.
    Primary Completion
    Sep 2028est.
    Completion
    Sep 2028est.
    NCT06526377
  • Phase 2
    Not yet recruiting

    Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

    Natrunix 400 mg, Placebo

    Rheumatoid Arthritis

    Enrollment
    108
    Start
    Jul 2026est.
    Primary Completion
    Jan 2027est.
    Completion
    Jul 2027est.
    NCT06590090
  • Phase 1/2
    Completed

    Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

    514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment

    Staphylococcus Aureus Bacteremia

    Enrollment
    52
    Start
    May 2015
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02357966
  • Phase 1/2
    Completed

    XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

    Phase I: XB2001 250 mg, Phase I: XB2001 500 mg

    Pancreatic Cancer

    Enrollment
    76
    Start
    May 2021
    Primary Completion
    Oct 2023
    Completion
    Jun 2025
    NCT04825288
  • Phase 1
    Completed

    Hutrukin to Analyze Safety and PK in Healthy Volunteers

    Hutrukin, Placebo

    Pharmacokinetics

    Enrollment
    24
    Start
    Apr 2023
    Primary Completion
    Oct 2023
    Completion
    Apr 2024
    NCT05098080
  • Phase 1
    Completed

    Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

    Natrunix, Placebo

    Pharmacokinetics

    Enrollment
    24
    Start
    Jan 2022
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT05099510
Search ClinicalTrials.gov for “XBiotech”